Shenzhen-based pharma company focused on cardiovascular and metabolic drugs, expanding into innovative biologics.
Shenzhen-based pharma company focused on cardiovascular and metabolic drugs, expanding into innovative biologics.
Sells mainly cardiovascular prescription drugs to hospitals; its original mainstay, the anti-clot drug clopidogrel, lost ground when China's state volume-based purchasing rounds forced generic prices down. It has since leaned on newer heart-failure and blood-pressure drugs and is investing in biologic medicines still in development.
Moat: narrow (brand, regulatory licence). Established cardiovascular drug franchise and regulatory approvals built over two decades.
Headquarters: Shenzhen, China · Employees: 4,087
Size Shenzhen Salubris Pharmaceuticals (002294.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $4.31B, the 558th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥26.80 on 18 Nov 2026.
Performance Over six months the shares fell 24.0%, against +10.4% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue grew 14.2% over the last twelve months (peer median +3.0%); the operating margin is 11.3% (peer median 17.5%).
Valuation It trades at 35.4× forward earnings against a peer median of 25.2× (5th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.9 points above its cost of capital (5.0% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.85B | CN¥4.31B | CN¥3.98B | CN¥3.34B | CN¥3.45B |
| Revenue growth | — | +8% | +19% | -3% | — |
| Gross profit | CN¥3.86B | CN¥3.13B | CN¥2.81B | CN¥2.21B | CN¥2.37B |
| EBITDA | n/a | CN¥1.07B | CN¥1.08B | CN¥927M | CN¥922M |
| Net income | CN¥715M | CN¥652M | CN¥602M | CN¥580M | CN¥637M |
| Free cash flow | CN¥200M | CN¥144M | CN¥607M | CN¥199M | CN¥379M |
| Capital expenditure | CN¥1.00B | CN¥974M | CN¥625M | CN¥671M | CN¥599M |
| Total debt | CN¥966M | CN¥711M | CN¥134M | CN¥63.5M | CN¥614M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shenzhen Salubris Pharmaceuticals 002294.SZ | $4.31B | -24% | +14% | 11% | 35.4× | 12.4% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% |
| Livzon Pharmaceutical 000513.SZ | $3.76B | +4% | -14% | 19% | 16.9× | -9.6% |
| Cspc Pharma 1093.HK | $12.0B | +10% | +25% | 28% | 9.1× | -10.7% |
| Huadong Medicine 000963.SZ | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% |
| Sbp 1177.HK | $12.2B | +5% | +15% | 30% | 17.5× | -5.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002294.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.9% | -1.3% | 5th lowest of 21 |
| 6-month return | -24.0% | +10.4% | 3rd lowest of 20 |
| Distance from 52-week high | -62.2% | -25.9% | 2nd lowest of 21 |
| Revenue growth (TTM) | +14.2% | +3.0% | 6th highest of 19 |
| Operating margin | 11.3% | 17.5% | 6th lowest of 19 |
| Forward P/E | 35.4× | 25.2× | 5th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 12.4% | 3.2% | 7th most demanding of 17 |
| Growth delivered (Del g) | +9.7% | +5.8% | 7th highest of 17 |
| Hurdle (Req g minus delivered) | +2.7 pp | -5.0 pp | 6th most demanding of 17 |
| ROIC minus cost of capital | +2.9 pp | +7.0 pp | 7th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $4.31B | -24% | +14% | 11% | 35.4× | 12.4% | +9.7% |
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 45.1× | 7.9% | +46.5% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 16.2× | -9.9% | +0.3% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.38B | +1% | +25% | 25% | 31.7× | 23.8% | +13.8% |
| Guangzhou Baiyunshan Pharmaceutical 600332.SS | China | $4.45B | -13% | +1% | 3% | 12.9× | -0.7% | +4.7% |
| Santen Pharmaceutical 4536.T | Japan | $4.14B | +10% | +2% | 16% | 16.7× | -5.0% | +3.2% |
| Yuhan 000100.KS | South Korea | $4.11B | -10% | +8% | 6% | 40.4× | n/a | n/a |
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | n/a | n/a | n/a |
| Definium Therapeutics DFTX | United States | $3.99B | +40% | n/a | n/a | n/a | n/a | n/a |
| HanmiPharm 128940.KS | South Korea | $3.95B | -2% | +14% | 16% | 15.0× | 4.7% | +7.5% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.74B | +37% | +21% | 16% | 33.6× | 15.9% | +12.7% |
| Novast Laboratories 301569.SZ | China | $3.92B | n/a | +3% | 27% | n/a | 57.4% | +3.1% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.79B | +10% | +12% | 33% | 37.3× | 26.4% | +5.5% |
| Travere Therapeutics TVTX | United States | $4.82B | +16% | +49% | -3% | 17.1× | 17.3% | +19.9% |
| Erasca ERAS | United States | $4.83B | +24% | n/a | n/a | n/a | n/a | n/a |
| Humanwell Healthcare (Group) 600079.SS | China | $4.87B | +11% | +2% | 15% | 13.8× | -8.8% | +3.0% |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $3.81B | -38% | +227% | 74% | 39.9× | 0.9% | +45.1% |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 28.7× | 1.7% | +6.2% |
| Livzon Pharmaceutical 000513.SZ | China | $3.76B | +4% | -14% | 19% | 16.9× | -9.6% | +2.7% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $3.75B | -10% | -13% | 20% | 28.5× | 16.2% | -5.8% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.75B | +12% | +14% | 20% | 21.9× | 1.2% | +12.1% |